Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression

被引:47
作者
Cavazzana, Ilaria [1 ]
Angela, Ceribelli [1 ]
Paolo, Airo' [1 ]
Stefania, Zingarelli [1 ]
Angela, Tincani [1 ]
Franco, Franceschini [1 ]
机构
[1] Spedali Civil Brescia, Reumatol & Immunol Clin, Rheumatol Unit & Chair, I-25100 Brescia, Italy
关键词
Anti-RNA polymerase III; Systemic Sclerosis; Anti-nuclear antibodies; Raynaud's phenomenon; Rapid systemic sclerosis onset; Skin thickening progression; SERUM ANTINUCLEAR ANTIBODIES; LINKED-IMMUNOSORBENT-ASSAY; CLINICAL ASSOCIATIONS; KU ANTIBODIES; AUTOANTIBODIES; SCLERODERMA; IDENTIFICATION; PATHOGENESIS; PREVALENCE; INSIGHTS;
D O I
10.1016/j.autrev.2009.02.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anti-RNA polymerase III antibodies (ARA) are a specific marker for Systemic Sclerosis (SSc), associated to severe disease with major organ and diffuse cutaneous involvement. In our series, ARA were found in 19 of 216 sera, in 15 cases as isolated antibodies' specificity, with a statistically negative association with other SSc-specific autoantibodies (p: 0.00003). The prevalence of ARA among 73 anticentromere and anti-topoisomerase I (topo 1) negative sera, was 20.5%. Patients with isolated ARA had more rapid disease onset, defined as the interval from the appearance of Raynaud's phenomenon to the first symptom other than Raynaud's, than patients with isolated anti-topo I antibodies (median: 2 months vs 13 months; p: 0.0013). A rapid onset of SSc (within 6 months from Raynaud's phenomenon onset) was found in all patients with isolated ARA and only in 34% of those with anti-topo I (p<0.00001). Moreover, the skin thickening in the first months after SSc onset was faster in the ARA group (p<0.0001). Nevertheless, the rates of internal organ involvement and of survival rates were similar between the two groups. Our experience therefore suggests that ARA are a marker of very rapid onset of disease and skin thickening progression in SSc. (C) 2009 Published by Elsevier B.V.
引用
收藏
页码:580 / 584
页数:5
相关论文
共 35 条
[1]  
Bardoni A, 2003, CLIN EXP RHEUMATOL, V21, P301
[2]   IDENTIFICATION OF ANTIBODIES TO ACIDIC ANTIGENS BY COUNTERIMMUNOELECTROPHORESIS [J].
BERNSTEIN, RM ;
BUNN, CC ;
HUGHES, GRV .
ANNALS OF THE RHEUMATIC DISEASES, 1982, 41 (05) :554-555
[3]  
Bunn CC, 1998, BRIT J RHEUMATOL, V37, P15
[4]   Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases [J].
Cavazzana, I. ;
Ceribelli, A. ;
Quinzanini, M. ;
Scarsi, M. ;
Airo, P. ;
Cattaneo, R. ;
Franceschini, F. .
LUPUS, 2008, 17 (08) :727-732
[5]  
CLARK G, 1969, J IMMUNOL, V102, P117
[6]  
CLEMENTS P, 1995, J RHEUMATOL, V22, P1277
[7]  
Codullo V, 2007, CLIN EXP RHEUMATOL, V25, P373
[8]   STANDARDIZATION OF THE MEASUREMENT OF TRANSFER-FACTOR (DIFFUSING-CAPACITY) - REPORT WORKING PARTY STANDARDIZATION OF LUNG-FUNCTION TESTS EUROPEAN-COMMUNITY FOR STEEL AND COAL - OFFICIAL STATEMENT OF THE EUROPEAN RESPIRATORY SOCIETY [J].
COTES, JE ;
CHINN, DJ ;
QUANJER, PH ;
ROCA, J ;
YERNAULT, JC .
EUROPEAN RESPIRATORY JOURNAL, 1993, 6 :41-52
[9]   Systemic sclerosis: current views of its pathogenesis [J].
Derk, CT ;
Jimenez, SA .
AUTOIMMUNITY REVIEWS, 2003, 2 (04) :181-191
[10]   Anti-RNA polymerase antibodies in systemic sclerosis (SSc): Association with anti-topoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II [J].
Harvey, GR ;
Rands, AL ;
McHugh, NJ .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 105 (03) :468-474